Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
$54.65
+0.2%
$54.50
$37.28
▼
$57.35
$4.50B-0.41.86 million shs15.31 million shs
Oklo Inc. stock logo
OKLO
Oklo
$19.81
-4.9%
$30.20
$18.53
▼
$115.72
$4.50B1.3110.34 million shs13.53 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
0.00%0.00%0.00%0.00%+0.57%
Oklo Inc. stock logo
OKLO
Oklo
-4.72%-17.01%-28.62%-53.01%-80.71%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
$54.65
+0.2%
$54.50
$37.28
▼
$57.35
$4.50B-0.41.86 million shs15.31 million shs
Oklo Inc. stock logo
OKLO
Oklo
$19.81
-4.9%
$30.20
$18.53
▼
$115.72
$4.50B1.3110.34 million shs13.53 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
0.00%0.00%0.00%0.00%+0.57%
Oklo Inc. stock logo
OKLO
Oklo
-4.72%-17.01%-28.62%-53.01%-80.71%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
3.00
BuyN/AN/A
Oklo Inc. stock logo
OKLO
Oklo
2.57
Moderate Buy$66.11233.70% Upside

Current Analyst Ratings Breakdown

Latest AKRO and OKLO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/20/2026
Oklo Inc. stock logo
OKLO
Oklo
UpgradeNeutral ➝ Buy$38.00
11/13/2026
Oklo Inc. stock logo
OKLO
Oklo
Lower Price TargetHold$31.00 ➝ $28.00
11/9/2026
Oklo Inc. stock logo
OKLO
Oklo
Lower Price TargetBuy$100.00 ➝ $66.00
11/9/2026
Oklo Inc. stock logo
OKLO
Oklo
Reiterated RatingOutperform$36.00
11/9/2026
Oklo Inc. stock logo
OKLO
Oklo
Reiterated RatingBuy$90.00
11/4/2026
Oklo Inc. stock logo
OKLO
Oklo
Reiterated RatingSell (D-)
11/3/2026
Oklo Inc. stock logo
OKLO
Oklo
Initiated CoverageOutperform$36.00
10/28/2026
Oklo Inc. stock logo
OKLO
Oklo
Lower Price TargetBuy$92.00 ➝ $61.00
10/26/2026
Oklo Inc. stock logo
OKLO
Oklo
Initiated CoverageHold$26.00
10/22/2026
Oklo Inc. stock logo
OKLO
Oklo
Lower Price TargetHold$51.00 ➝ $31.00
(Data available from 11/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/AN/AN/AN/A$10.75 per shareN/A
Oklo Inc. stock logo
OKLO
Oklo
N/AN/AN/AN/A$18.68 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
-$252.06M-$1.94N/AN/AN/AN/A-15.86%-14.78%N/A
Oklo Inc. stock logo
OKLO
Oklo
-$105.66M-$0.96N/AN/AN/AN/A-6.36%-6.18%N/A

Latest AKRO and OKLO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2026Q3 2026
Oklo Inc. stock logo
OKLO
Oklo
-$0.2695-$0.22+$0.0495-$0.22$1.03 million$1.86 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/AN/AN/AN/AN/A
Oklo Inc. stock logo
OKLO
Oklo
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/A
15.84
15.83
Oklo Inc. stock logo
OKLO
Oklo
N/A
31.20
31.20

Institutional Ownership

CompanyInstitutional Ownership
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/A
Oklo Inc. stock logo
OKLO
Oklo
85.03%

Insider Ownership

CompanyInsider Ownership
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
7.07%
Oklo Inc. stock logo
OKLO
Oklo
12.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
3082.32 million76.50 millionOptionable
Oklo Inc. stock logo
OKLO
Oklo
205195.29 million170.49 millionOptionable

Recent News About These Companies

Nuclear Stocks To Watch Today - November 21st
Oklo (NYSE:OKLO) Shares Down 4.9% - Here's What Happened
Best Nuclear Stocks To Watch Today - November 20th
Oklo (NYSE:OKLO) Stock Lifted to "Buy" by Guggenheim
Oklo (NYSE:OKLO) Stock Price Down 2.6% Following Insider Selling
Oklo (NYSE:OKLO) Stock Price Down 4.6% - Here's Why
Could $1,000 in Oklo Stock Set You Up for Life by 2035?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Akero Therapeutics stock logo

Akero Therapeutics NASDAQ:AKRO

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Oklo stock logo

Oklo NYSE:OKLO

$19.81 -1.03 (-4.94%)
Closing price 11/20/2026 03:59 PM Eastern
Extended Trading
$20.24 +0.43 (+2.17%)
As of 11/20/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Oklo Inc. designs and develops fission power plants to provide reliable and commercial-scale energy to customers in the United States. It also provides used nuclear fuel recycling services. The company was founded in 2013 and is based in Santa Clara, California.